The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Chuikyo Plans Monthly Debates for CEA Reform in FY2026
May 15, 2025
-
REGULATORY Epkinly, Lunsumio to Face Price Cut of 2.7% under CEA Scheme
May 15, 2025
-
REGULATORY Japan’s Parliament Enacts Bill to Amend PMD Act
May 15, 2025
-
REGULATORY LDP Group Proposes Higher Cap on Social Security Budgets, Category-Based Drug Pricing
May 14, 2025
-
ACADEMIA Japan Consortium to Promote Domestic R&D of Cannabis-Derived Meds
May 14, 2025
-
BUSINESS J&J Taps Chris Rieger to Lead Japan Pharma Business
May 13, 2025
-
REGULATORY MHLW Council Deems 11 “Loss” Products as Medically Highly Necessary
May 12, 2025
-
BUSINESS Takeda on Course to Stable Growth as Late-Stage Assets Near Market
May 9, 2025
-
BUSINESS Lilly Japan Scores Double-Digit Growth for 2nd Year as Mounjaro Delivers
May 9, 2025
-
BUSINESS Shionogi to Buy Torii in 160 Billion Yen Deal, JT Pulls Plug on Pharma Biz
May 8, 2025
-
COMMENTARY New Grad Hires for Sales Reps Up after 5 Years of Decrease: FY2025 Survey
May 8, 2025
-
REGULATORY MHLW to Set Up Special Panel for High-Cost Medical Expense Benefit Program
May 7, 2025
-
BUSINESS Kyowa Kirin’s New Skipper Sees Further Growth Overseas, Vows to Cherish People
May 1, 2025
-
BUSINESS Astellas Gears Up for Xtandi Patent Cliff with Next-Gen Assets, Cost Cuts
April 28, 2025
-
BUSINESS Novo Nordisk Logs 3.6% Growth in Japan in 2024, Driven by Semaglutide
April 28, 2025
-
BUSINESS Sanofi Looks to Join Top 3 in Japan Pharma Market by 2030
April 25, 2025
-
REGULATORY MOF’s Spring Debate Puts Special Focus on CEA, More Aggressive Re-Pricing Eyed
April 24, 2025
-
REGULATORY Epkinly to Face Price Cuts under CEA Scheme
April 24, 2025
-
BUSINESS Takeda’s Japan Earnings Bottomed Out, Now on Pace to Growth from FY2025: Head
April 23, 2025
-
REGULATORY GSK’s Blenrep, Moderna RSV Jab Edge Closer to Japan Approval with Panel OK
April 22, 2025
ページ
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…